A Sinopharm vaccine offers poor protection from Covid-19 among the elder, raising questions for dozens of countries that have given the Chinese company’s shots to their most vulnerable populations.
A blood samples taken from 450 people in Hungary at least 2 weeks after their second Sinopharm dose found that 90% under 50 years old developed protective antibodies. But the percentage declined with age, and 50% of those over 80 had none.
Antibody levels are not a direct measure of how protected a person is from Covid-19, but there is growing evidence that they are a good proxy.
3 outside experts said they had no problems with the methodology of the study of the vaccine developed by Sinopharm’s Beijing Institute of Biological Products.
China’s National Health Commission declined on the study, it would only respond to studies by governments or major research institutions.
The vaccine is one of two similar shots spread by Sinopharm.
In Hungary, concern about many to seek out private antibody tests. Eventually the capital city of Budapest offered free testing to elder residents pressure on the government to conduct its own wider survey and provide booster shots to those who need them. A government response to efficacy concerns including from the antibody study’s authors Balazs Sarkadi and Tamas Ferenci Prime Minster Viktor Orban finally acquiesced last week in the face of growing public anger.
The United Arab Emirates and Bahrain both announced in May that they would offer a third dose of Sinopharm concerns about an insufficient antibody response.
Sinopharm both vaccines are also in wide use in Chin. The country’s National Health Commission said in April that the shots provide some protection, even though it acknowledged that early stages of clinical trials of Sinopharm’s vaccines and two others found fewer antibodies in people 60 and over.
The Global Alliance for Vaccines and Immunization recently ordered 550 million doses from the two companies the U.N.-backed COVAX program.
Which was given a greenlight by the World Health Organization in May and is being used in more than 50 countries the efficacy of the vaccine.